KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Non-Current Debt (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Non-Current Debt for 16 consecutive years, with $31.2 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Debt rose 2.32% year-over-year to $31.2 billion, compared with a TTM value of $31.2 billion through Sep 2024, up 2.32%, and an annual FY2023 reading of $31.3 billion, up 8.3% over the prior year.
  • Non-Current Debt was $31.2 billion for Q3 2024 at Thermo Fisher Scientific, up from $30.3 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $32.3 billion in Q4 2021 and bottomed at $18.6 billion in Q2 2021.
  • Average Non-Current Debt over 5 years is $26.4 billion, with a median of $29.1 billion recorded in 2023.
  • The sharpest move saw Non-Current Debt soared 69.22% in 2021, then dropped 10.59% in 2022.
  • Year by year, Non-Current Debt stood at $19.1 billion in 2020, then skyrocketed by 69.22% to $32.3 billion in 2021, then decreased by 10.59% to $28.9 billion in 2022, then grew by 8.3% to $31.3 billion in 2023, then decreased by 0.35% to $31.2 billion in 2024.
  • Business Quant data shows Non-Current Debt for TMO at $31.2 billion in Q3 2024, $30.3 billion in Q2 2024, and $31.2 billion in Q1 2024.